Jag Capital Management LLC Acquires 26,394 Shares of Natera, Inc. (NASDAQ:NTRA)

Jag Capital Management LLC grew its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 25.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 129,679 shares of the medical research company's stock after buying an additional 26,394 shares during the quarter. Natera makes up about 2.4% of Jag Capital Management LLC's investment portfolio, making the stock its 17th biggest position. Jag Capital Management LLC owned 0.10% of Natera worth $18,338,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of NTRA. LRI Investments LLC acquired a new stake in Natera in the 4th quarter valued at about $29,000. Rakuten Securities Inc. raised its position in shares of Natera by 117.8% during the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC bought a new stake in shares of Natera during the first quarter worth $32,000. EverSource Wealth Advisors LLC lifted its stake in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares during the period. Finally, Principal Securities Inc. boosted its holdings in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after acquiring an additional 59 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Wall Street Zen lowered shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Royal Bank Of Canada began coverage on Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. Piper Sandler raised their price target on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. UBS Group increased their target price on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Finally, Morgan Stanley raised their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Natera Price Performance

Shares of NTRA traded down $8.22 during mid-day trading on Tuesday, hitting $160.72. 1,318,102 shares of the company's stock were exchanged, compared to its average volume of 1,420,895. The company has a 50-day simple moving average of $159.46 and a 200 day simple moving average of $158.49. The company has a market cap of $21.95 billion, a PE ratio of -109.33 and a beta of 1.74. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The company's revenue for the quarter was up 36.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.56) EPS. On average, analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity

In other news, Director Gail Boxer Marcus sold 4,000 shares of the business's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $151.61, for a total transaction of $606,440.00. Following the transaction, the director directly owned 9,704 shares in the company, valued at $1,471,223.44. The trade was a 29.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 6,980 shares of the firm's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $150.10, for a total transaction of $1,047,698.00. Following the completion of the sale, the chief executive officer owned 185,182 shares of the company's stock, valued at $27,795,818.20. This trade represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,630 shares of company stock valued at $6,235,808 over the last three months. Corporate insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.